| Code | CSB-RA017260MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20150064201A1, targeting oncostatin M (OSM), a pleiotropic cytokine belonging to the interleukin-6 family. OSM plays critical roles in inflammation, hematopoiesis, tissue remodeling, and bone metabolism by signaling through heterodimeric receptor complexes composed of gp130 and either OSMR or LIFR. Dysregulated OSM expression has been implicated in various pathological conditions, including inflammatory diseases, fibrotic disorders, cardiovascular disease, and multiple cancer types where it influences tumor progression, metastasis, and the tumor microenvironment.
The reference antibody was developed to neutralize OSM activity and has been investigated for therapeutic potential in inflammatory and oncological contexts. This biosimilar provides researchers with a high-quality tool for investigating OSM-mediated signaling pathways, exploring its role in disease pathogenesis, and evaluating OSM as a therapeutic target. The antibody enables studies examining cytokine networks, cellular differentiation processes, and inflammatory responses in relevant experimental models.
There are currently no reviews for this product.